Get the Stockscreener App
302.51
4.36%
12.63
After Hours:
302.51
Madrigal Pharmaceuticals Inc stock is traded at $302.51, with a volume of 535.48K.
It is up +4.36% in the last 24 hours and down -0.04% over the past month.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.
See More
Previous Close:
$289.88
Open:
$291
24h Volume:
535.48K
Relative Volume:
1.57
Market Cap:
$6.72B
Revenue:
-
Net Income/Loss:
$-518.67M
P/E Ratio:
-12.04
EPS:
-25.12
Net Cash Flow:
$-438.32M
1W Performance:
+1.12%
1M Performance:
-0.04%
6M Performance:
-9.64%
1Y Performance:
+6.27%
1-Day Range:
$290.00
$312.05
1-Week Range:
$286.44
$312.05
52-Week Range:
$200.63
$377.46
Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile
Name
Madrigal Pharmaceuticals Inc
Sector
Industry
Phone
404-380-9263
Address
200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA
Compare MDGL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MDGL
Madrigal Pharmaceuticals Inc
|
302.51 | 6.44B | 0 | -518.67M | -438.32M | -25.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.87 | 120.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.46 | 59.88B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.24 | 44.31B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
670.33 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
301.13 | 32.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-28-25 | Upgrade | B. Riley Securities | Neutral → Buy |
| Feb-27-25 | Reiterated | H.C. Wainwright | Buy |
| Jun-28-24 | Initiated | Cantor Fitzgerald | Neutral |
| Jun-11-24 | Initiated | Wolfe Research | Outperform |
| Apr-22-24 | Initiated | BofA Securities | Underperform |
| Mar-15-24 | Upgrade | B. Riley Securities | Sell → Neutral |
| Mar-06-24 | Initiated | Citigroup | Buy |
| Feb-26-24 | Downgrade | B. Riley Securities | Neutral → Sell |
| Dec-20-22 | Reiterated | Oppenheimer | Outperform |
| Dec-19-22 | Reiterated | H.C. Wainwright | Buy |
| Dec-19-22 | Reiterated | Piper Sandler | Overweight |
| Dec-19-22 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Jul-08-22 | Downgrade | B. Riley Securities | Buy → Neutral |
| Oct-07-21 | Initiated | Jefferies | Buy |
| Aug-06-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| May-20-21 | Resumed | Goldman | Buy |
| Nov-24-20 | Resumed | Evercore ISI | Outperform |
| Nov-06-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-31-20 | Initiated | Piper Sandler | Overweight |
| Jun-05-20 | Initiated | BMO Capital Markets | Market Perform |
| May-05-20 | Initiated | Chardan Capital Markets | Buy |
| Jan-30-20 | Initiated | Canaccord Genuity | Buy |
| Jan-09-20 | Upgrade | UBS | Neutral → Buy |
| Nov-07-19 | Reiterated | H.C. Wainwright | Buy |
| Jun-25-19 | Initiated | Stifel | Hold |
| Jun-10-19 | Upgrade | B. Riley FBR | Neutral → Buy |
| Feb-28-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-22-19 | Initiated | SVB Leerink | Outperform |
| Jan-23-19 | Initiated | UBS | Neutral |
| Dec-14-18 | Initiated | Wolfe Research | Outperform |
| Dec-12-18 | Initiated | B. Riley FBR | Neutral |
| Nov-19-18 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Nov-16-18 | Upgrade | Evercore ISI | In-line → Outperform |
| Sep-04-18 | Initiated | Citigroup | Buy |
| Aug-06-18 | Downgrade | Goldman | Buy → Neutral |
| Jun-28-18 | Initiated | Raymond James | Mkt Perform |
View All
Madrigal Pharmaceuticals Inc Stock (MDGL) Latest News
Madrigal Pharmaceuticals: Rezdiffra Expansion Avenues Shift Focus To Long Term (MDGL) - Seeking Alpha
What makes Madrigal Pharmaceuticals Inc. stock price move sharplyFinancial News Guidance For Beginners - jammulinksnews.com
How strong is Madrigal Pharmaceuticals Inc. company’s balance sheetMarket Forecast Review For 2025 - jammulinksnews.com
Madrigal in-pact with CSPC Pharma for obesity drug license - MSN
Analyzing recovery setups for Madrigal Pharmaceuticals Inc. investorsSwing Trade Entry With Volume Triggers Released - metal.it
Non-Alcoholic Steatohepatitis Market Set to Grow - openPR.com
GLP-1, Rezdiffra MASH-up eyed in $2B Madrigal/CSPC deal - BioWorld MedTech
Madrigal Pharmaceuticals Enters into Exclusive Global - GlobeNewswire
Madrigal Pharmaceuticals Secures $500 Million Credit Facility to Expand MASH Pipeline - MSN
Madrigal Pharmaceuticals' Strategic Licensing Deal: A Pivotal Move in the NASH Therapeutics Arms Race - AInvest
Madrigal inks license deal with CSPC Pharma - The Pharma Letter
Madrigal in-pact with CSPC Pharma for GLP-1 candidate license - Seeking Alpha
Madrigal obtains rights to CSPC Pharmaceutical’s SYH-2086 - BioWorld MedTech
Madrigal Pharmaceuticals Signs Global License Agreement - TipRanks
Madrigal secures global license for oral GLP-1 drug to combine with Rezdiffra - Investing.com Nigeria
Madrigal Pharmaceuticals Enters into Exclusive Global License Agreement for Oral GLP-1 Receptor Agonist with CSPC Pharmaceutical Group Limited | MDGL Stock News - GuruFocus
Madrigal Pharmaceuticals Enters Exclusive License Agreement with CSPC for SYH2086 to Enhance MASH Treatment Pipeline - Quiver Quantitative
Madrigal secures global license for oral GLP-1 drug to combine with Rezdiffra By Investing.com - Investing.com South Africa
CSPC Pharmaceutical Secures $2 Billion Licensing Deal with Madrigal - AInvest
Madrigal and CSPC Pharmaceutical sign up to $2 billion licensing deal - TradingView
Madrigal's $2B Oral GLP-1 Deal Aims to Create Best-in-Class MASH Combination Therapy - Stock Titan
Published on: 2025-07-29 15:17:14 - metal.it
Madrigal Pharmaceuticals, Inc. (MDGL)’s Rezdiffra Hits 51% Liver Stiffness Reduction in Phase 3 - MSN
Madrigal Pharmaceuticals’ SWOT analysis: rezdiffra’s strong launch fuels stock outlook - Investing.com
Madrigal (MDGL) Secures $500M to Fuel MASH Pipeline Expansion - MSN
Does Madrigal Pharmaceuticals Inc. stock perform well during market downturnsSwing Trade Outlook For Every Investor - jammulinksnews.com
Madrigal Pharmaceuticals to Announce Q2 2025 Results with Live Webcast - MSN
Why Madrigal Pharmaceuticals Inc. stock attracts strong analyst attentionTriple Digit Return Stock Predictions Released - metal.it
How many analysts rate Madrigal Pharmaceuticals Inc. as a “Buy”Invest smarter with advanced market data - jammulinksnews.com
What are Madrigal Pharmaceuticals Inc. company’s key revenue driversConsistently high yield - jammulinksnews.com
How volatile is Madrigal Pharmaceuticals Inc. stock compared to the marketAchieve fast wealth growth with smart picks - jammulinksnews.com
Is Madrigal Pharmaceuticals Inc. a growth stock or a value stockFree Stock Market Trend Analysis - jammulinksnews.com
How Efficient Is Madrigal Pharmaceuticals Inc. at Controlling Operating CostsHigh Reward Risk Balanced Trading - metal.it
Madrigal Pharmaceuticals to Release Second-Quarter 2025 Financial Results and Host Webcast on August 5, 2025 - GlobeNewswire
Madrigal Pharmaceuticals Inc. Stock Analysis and ForecastSkyrocketing investment returns - Autocar Professional
Madrigal Pharmaceuticals to Release Second-Quarter 2025 Financia - GuruFocus
Madrigal Pharmaceuticals, Inc. Announces Second-Quarter 2025 Financial Results Release and Webcast Details - Quiver Quantitative
Madrigal Pharmaceuticals to Release Second-Quarter 2025 Financial Results and Host Webcast on August 5, 2025 - GlobeNewswire Inc.
What drives Madrigal Pharmaceuticals Inc. stock priceRemarkably fast returns - PrintWeekIndia
Madrigal Pharmaceuticals: Strengthened Financial Position and Promising Pipeline Expansion Drive Buy Rating - TipRanks
Madrigal Pharmaceuticals secures $500M credit facility from Blue Owl - MSN
Madrigal Pharmaceuticals: Strategic Financing and Growth Potential Justify Buy Rating - TipRanks
Is Madrigal Pharmaceuticals Inc. a good long term investmentHigh-profit trading signals - jammulinksnews.com
What analysts say about Madrigal Pharmaceuticals Inc. stockSuperior portfolio returns - jammulinksnews.com
Madrigal Pharmaceuticals Inc Stock (MDGL) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.43%
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):